JP2022503879A - がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ - Google Patents

がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ Download PDF

Info

Publication number
JP2022503879A
JP2022503879A JP2021517484A JP2021517484A JP2022503879A JP 2022503879 A JP2022503879 A JP 2022503879A JP 2021517484 A JP2021517484 A JP 2021517484A JP 2021517484 A JP2021517484 A JP 2021517484A JP 2022503879 A JP2022503879 A JP 2022503879A
Authority
JP
Japan
Prior art keywords
alkyl
receptor antagonist
adenosine receptor
ent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517484A
Other languages
English (en)
Japanese (ja)
Inventor
ステファノ クロシニャーニ，
エリカ ヨーケ カテライネ ヘレーン ハウトハイス，
エノ， オリヴィエ ドゥ
Original Assignee
アイテオ ベルギウム エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BE20180115A external-priority patent/BE1026612B1/fr
Application filed by アイテオ ベルギウム エスエー filed Critical アイテオ ベルギウム エスエー
Publication of JP2022503879A publication Critical patent/JP2022503879A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
JP2021517484A 2018-09-27 2019-09-27 がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ Pending JP2022503879A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737717P 2018-09-27 2018-09-27
US62/737,717 2018-09-27
BE20180115A BE1026612B1 (fr) 2018-09-27 2018-09-27 Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
BE2018/0115 2018-09-27
PCT/EP2019/076244 WO2020065036A1 (fr) 2018-09-27 2019-09-27 Utilisation d'un inhibiteur d'un transporteur de la famille des ent dans le traitement du cancer et de la combinaison de ceux-ci avec un antagoniste du récepteur de l'adénosine

Publications (1)

Publication Number Publication Date
JP2022503879A true JP2022503879A (ja) 2022-01-12

Family

ID=68109305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517484A Pending JP2022503879A (ja) 2018-09-27 2019-09-27 がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ

Country Status (4)

Country Link
JP (1) JP2022503879A (fr)
BR (1) BR112021006033A2 (fr)
IL (1) IL281802A (fr)
WO (1) WO2020065036A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3601296T1 (sl) 2017-03-30 2022-10-28 iTeos Belgium SA 2-okso-tiazolni derivati kot zaviralci A2A in spojine za uporabo pri zdravljenju raka
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
AU2020395495B2 (en) * 2019-12-02 2024-05-09 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine
WO2022178135A1 (fr) 2021-02-17 2022-08-25 Iteos Belguim Sa Composés, compositions et procédés de traitement de ces derniers
WO2023056910A1 (fr) * 2021-10-06 2023-04-13 iTeos Belgium SA Procédés de préparation d'un composé macrocyclique ayant une activité inhibitrice de l'ent1
WO2023059739A1 (fr) * 2021-10-06 2023-04-13 iTeos Belgium SA Composés macrocycliques ayant une activité d'inhibition de l'ent1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140181A2 (fr) * 2006-05-26 2007-12-06 King Pharmaceuticals Research And Development, Inc. Polythérapie comprenant un inhibiteur de fixation de l'adénosine et un antagoniste des récepteurs de l'adénosine non sélectif
WO2009011897A1 (fr) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinaisons pour le traitement des troubles prolifératifs des lymphocytes b
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
CN102869631B (zh) 2010-02-08 2016-09-07 埃西勒国际通用光学公司 包含具有防雾性能的抗反射涂层的光学制品
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US20130267515A1 (en) * 2010-10-26 2013-10-10 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
KR102611446B1 (ko) 2017-01-20 2023-12-06 아르커스 바이오사이언시즈 인코포레이티드 암-관련 장애의 치료를 위한 아졸로피리미딘
WO2018178338A1 (fr) 2017-03-30 2018-10-04 Iteos Therapeutics Dérivés de 2-oxo-thiazole en tant qu'inhibiteurs de a2a et composés destinés à être utilisés dans le traitement de cancers

Also Published As

Publication number Publication date
IL281802A (en) 2021-05-31
WO2020065036A1 (fr) 2020-04-02
BR112021006033A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
JP2022503879A (ja) がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ
EP3119397B1 (fr) Composés hétérocycliques destinés à être utilisés dans le traitement de troubles médiés par pi3k-gamma
US20230121530A1 (en) Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
JP2019059778A (ja) 置換ピリミジンＢｍｉ−１阻害剤
AU2013202993B2 (en) Treatment of cancer with TOR kinase inhibitors
CN113474337A (zh) 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN107667092B (zh) 作为fgfr4抑制剂的甲酰化n-杂环衍生物
KR20160004305A (ko) Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
JP2019070012A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
AU2014254057A1 (en) Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
KR20180013850A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
JP2021531311A (ja) ナフチリジン化合物およびその使用
TW202108572A (zh) Ｃｄｋ抑制劑
WO2014134240A1 (fr) Traitement du cancer avec des inhibiteurs de la kinase tor
JP2018534263A (ja) 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ
JP2021523114A (ja) リンパ腫の治療方法
US20210346384A1 (en) Combinations of tgf-beta inhibitors and cdk inhibitors for cancer treatments
WO2022204721A1 (fr) Inhibiteurs d'alk-5 et leurs utilisations
JP2022507514A (ja) Ｅｒｋインヒビター及びその使用
EP3856181A1 (fr) Utilisation d'un inhibiteur d'un transporteur de la famille des ent dans le traitement du cancer et de la combinaison de ceux-ci avec un antagoniste du récepteur de l'adénosine
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
RU2784852C2 (ru) КОМБИНАЦИИ ИНГИБИТОРОВ TGFβ И ИНГИБИТОРОВ CDK ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
JPWO2009110415A1 (ja) 併用剤
WO2023249974A2 (fr) Inhibiteurs de kinase 2 dépendantes des cyclines pour un traitement médical
KR20230010659A (ko) Sumo-활성화 효소 억제제 및 항-cd38 항체의 투여

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240209